Adaptive Biotechnologies
ISIN US00650F1093
|WKN A2PLR5
Overview
Description
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Healthcare Healthcare Services Miscellaneous Healthcare United States
Financials
Key metrics
| Market capitalisation, EUR | 990.24 m |
| EPS, EUR | -1.00 |
| P/B ratio | 5.40 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 165.44 m |
| Net income, EUR | -147.45 m |
| Profit margin | -89.12% |
What ETF is Adaptive Biotechnologies in?
There are 9 ETFs which contain Adaptive Biotechnologies. All of these ETFs are listed in the table below. The ETF with the largest weighting of Adaptive Biotechnologies is the ARK Genomic Revolution UCITS ETF USD Accumulating.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
